Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 5

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 5
---
We are registering up to 5,724,837,950,000 Ordinary Shares (in the form of Depositary Shares) under this prospectus, including Ordinary Shares (in the form of Depositary Shares) issuable if the holders of the Series L Warrants elect the zerocash exercise price option. As of June 30, 2025, there were 61,952,308,922 Ordinary Shares outstanding. If all of the Ordinary Shares (represented by Depositary Shares) offered under this prospectus were issued and outstanding as of June 30, 2025, such shares would represent approximately 98.9% of total number of Ordinary Shares issued and outstanding.

The Depositary Shares and Pre-Funded Warrants, and the accompanying Series L Warrants, as the case may be, can only be purchased together in this offering but will be issued separately and will be immediately separable upon issuance. Pursuant to the registration statement related to this prospectus, we are also registering the Depositary Shares issuable upon exercise of the Series L Warrants and Pre-Funded Warrants included in the Units and Pre-Funded Units offered hereby.

For each Pre-Funded Unit we
sell (without regard to any limitation on exercise set forth therein), the number of Units we are offering will be decreased on a one-for-one
basis. Because a Series L Warrant is being sold together in this offering with each Depositary Share and, in the alternative, each Pre-Funded
Warrant to purchase one Depositary Share, the number of Series L Warrants sold in this offering will not change as a result of a change
in the mix of the Depositary Shares and Pre-Funded Warrants sold.

Our Depositary Shares are
listed on the NASDAQ Capital Market under the symbol “BDRX.” On November 14, 2025, the last reported sale price of our Depositary
Shares on the NASDAQ Capital Market was $5.26 per share. All Depositary Share, Pre-Funded Warrant and Series L Warrant numbers are based
on an assumed combined public offering price of $5.33 per Unit, which is based upon the closing price of our Depositary Shares on
the NASDAQ Capital Market on November 12, 2025. The actual public offering price will be determined through negotiation between us and
the placement agent in the offering and may be at a discount to the current market price. Therefore, the assumed combined public offering
price used throughout this prospectus may